目的 探讨经肝动脉灌注栓塞术(TACE)联合CT导向下放射性125I粒子瘤内植人治疗肝癌的疗效。方法 回顾性分析75例确诊为原发性肝癌的患者,A组41例（单纯TACE组），B组34例（TACE序贯125I粒子植入术组），两组均于术后第3、6、12个月行CT扫描进行疗效评价，分别比较两组术后6个月、12个月的生存状态。两组有效率及生存状态比较 均采用卡方检验，以P <0.05为差异有统计学意义。结果术 后3个月，A、B组的总体有效率（CR +PR)分别为36.6% (15/41)、70.6% (24/34)，差异有统计学意义（P = 0. 005); B组术后6个月、1年生存率分别为97. 1 % (33/34)、5.3% (29/34)，明显高于A组的73. 2% (30/41 )、41.5%( 17/41 )(P<0.01)。结论TACE联合CT导向下放射性¹²⁵I粒子瘤内植入是治疗肝癌的安全有效的方法，具有良好的应用前景。

Objective To investigate the technical points and the clinical effectiveness of transcatheter arterial chemoembolization (TACE) combined with CT-guided 125I seeds implantation for the treatment of liver cancer. Methods 75 cases of hepatic carcinoma were retrospectively collected and divided into group A (41 patients with TACE alone) and group B (35 patients with TACE combined with 125I seeds implantation sequential therapy).Efficacy evaluation was performed in 3 month，6 month and 1 year after the operation by CT scan，and the survival status of 6 month and 1 year were also recorded. Results The overall response (CR + PR) of group A and group B were 36. 6% ( 15/41 ) and 70. 6% (24/34 ) respectively at 3 months after operation with significant difference ( P = 0. 005 ) . The survival rate at 6 and 12 months in group B (97. 1% and 85. 3% ) were significantly higher than those in group A (73. 2% and 41. 5% ) (P <0.01). Conclusion TACE combined with CT- guided ¹²⁵I seeds implantation could be a safe and effective treatment for liver.